Completed

JW0108+C2407 for Dyslipidemia

What is being tested

JW0108 + C2407

+ JW0108 + C2407 placebo

Drug

Who is being recruted

Metabolic Diseases+1

+ Nutritional and Metabolic Diseases

+ Dyslipidemias

Over 19 Years

+4 Eligibility Criteria

See all eligibility criteria

How is the trial designed

Treatment Study

Phase 3

Interventional

Study Start: April 2025

See protocol details

Summary

Principal SponsorJW Pharmaceutical

Last updated: January 28, 2026

Sourced from a government-validated database.Claim as a partner

Study start date: April 3, 2025

Actual date on which the first participant was enrolled.

This clinical trial aims to test the effectiveness and safety of combining two medications, JW0108 and C2407, for treating patients with dyslipidemia. Dyslipidemia is a condition characterized by abnormal levels of lipids, such as cholesterol and triglycerides, in the blood, which can increase the risk of heart disease and stroke. By evaluating this combination treatment, the study hopes to find a more efficient way to manage lipid levels in patients, potentially offering a new option for those who struggle to keep their cholesterol in check with existing treatments. Participants in this study will receive the combination treatment of JW0108 and C2407, although the method of administration is not specified. The trial will compare the effects of this treatment to see if it effectively improves lipid levels while being safe for patients. Although specific outcome measures are not detailed, the study will likely assess changes in cholesterol or triglyceride levels and monitor any side effects to determine the overall safety and potential benefits of the treatment.

Official TitleA Multi-center, Randomized, Double-blind, Parallel, Phase Ⅲ Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of JW0108+C2407 in Patients With Dyslipidemia

NCT06955104

Principal SponsorJW Pharmaceutical

Last updated: January 28, 2026

Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

145 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.

Conditions

Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 19 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Metabolic DiseasesNutritional and Metabolic DiseasesDyslipidemiasLipid Metabolism Disorders

Criteria

2 inclusion criteria required to participate

Age of 19 years old at the time of written informed consent

Patients with dyslipidemia

2 exclusion criteria prevent from participating

Secondary dyslipidemia

Patient who does not meet the specified TG, LDL-C level

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.

Treatment Groups

Study Objectives

2 intervention groups are designated in this study

This study does not include a placebo group

Treatment Groups

Group I

Experimental

For 8weeks QD(Quaque Die)

Group II

Active Comparator

For 8weeks QD(Quaque Die)

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Suspended

Asan Medical Center

Seoul, South KoreaOpen Asan Medical Center in Google Maps

CompletedOne Study Center